- Home
- EXEL vs VFS Comparison
EXEL vs VFS Comparison
Compare EXEL & VFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- VFS
- Stock Information
- Founded
- EXEL 1994
- VFS 2017
- Country
- EXEL United States
- VFS Vietnam
- Employees
- EXEL N/A
- VFS N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- VFS Blank Checks
- Sector
- EXEL Health Care
- VFS Finance
- Exchange
- EXEL Nasdaq
- VFS Nasdaq
- Market Cap
- EXEL 10.0B
- VFS 8.8B
- IPO Year
- EXEL 2000
- VFS N/A
- Fundamental
- Price
- EXEL $34.59
- VFS $4.25
- Analyst Decision
- EXEL Buy
- VFS Strong Buy
- Analyst Count
- EXEL 17
- VFS 5
- Target Price
- EXEL $32.18
- VFS $9.20
- AVG Volume (30 Days)
- EXEL 1.7M
- VFS 1.3M
- Earning Date
- EXEL 02-04-2025
- VFS 11-26-2024
- Dividend Yield
- EXEL N/A
- VFS N/A
- EPS Growth
- EXEL 441.02
- VFS N/A
- EPS
- EXEL 1.55
- VFS N/A
- Revenue
- EXEL $2,081,598,000.00
- VFS $1,517,342,313.00
- Revenue This Year
- EXEL $20.59
- VFS N/A
- Revenue Next Year
- EXEL $1.50
- VFS $65.09
- P/E Ratio
- EXEL $22.41
- VFS N/A
- Revenue Growth
- EXEL 17.31
- VFS 64.54
- 52 Week Low
- EXEL $19.20
- VFS $2.26
- 52 Week High
- EXEL $36.97
- VFS $8.78
- Technical
- Relative Strength Index (RSI)
- EXEL 51.61
- VFS 49.05
- Support Level
- EXEL $34.30
- VFS $4.18
- Resistance Level
- EXEL $36.22
- VFS $4.57
- Average True Range (ATR)
- EXEL 0.75
- VFS 0.35
- MACD
- EXEL -0.29
- VFS -0.04
- Stochastic Oscillator
- EXEL 25.09
- VFS 18.20
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About VFS VinFast Auto Ltd.
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Automobiles, E-scooter, Spare parts & Aftermarket services. The Automobiles segment includes the design, development, manufacturing, and sales of cars and electric buses; The E-scooter segment includes the design, development, manufacturing, and sales of e-scooters; the Spare parts & Aftermarket services segment includes the sales of spare parts and rendering of aftermarket services for automobiles and e-scooters.